BMRN - Company ID 0001048477
BIOMARIN PHARMACEUTICAL INC has filed 2,709 public company documents between 1999 and 2026. The most frequent type is insider trade (1,585 filings), alongside the regular cadence of annual reports, quarterly reports, and event disclosures every public company must make. Use the filters to focus on one filing type, or flip the sort to trace the company's history from its earliest paperwork.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Type | Filing | Filed | Period covered | Open |
|---|---|---|---|---|
| DEFA14A | Proxy materials | 2mo ago2026-04-21 | - | View filing |
| DEFA14A | Proxy materials | 1y ago2025-04-08 | - | View filing |
| DEFA14A | Proxy materials | 2y ago2024-04-09 | - | View filing |
| DEFA14A | Proxy materials | 3y ago2023-04-11 | - | View filing |
| DEFA14A | Proxy materials | 4y ago2022-04-12 | - | View filing |
| DEFA14A | Proxy materials | 5y ago2021-05-17 | - | View filing |
| DEFA14A | Proxy materials | 5y ago2021-04-13 | - | View filing |
| DEFA14A | Proxy materials | 6y ago2020-04-14 | - | View filing |
| DEFA14A | Proxy materials | 7y ago2019-04-23 | - | View filing |
| DEFA14A | Proxy materials | 8y ago2018-04-24 | - | View filing |
| DEFA14A | Proxy materials | 9y ago2017-04-25 | - | View filing |
| DEFA14A | Proxy materials | 10y ago2016-04-25 | - | View filing |
| DEFA14A | Proxy materials | 11y ago2015-04-23 | - | View filing |
| DEFA14A | Proxy materials | 12y ago2014-04-22 | - | View filing |
| DEFA14A | Proxy materials | 13y ago2013-04-05 | - | View filing |
| DEFA14A | Proxy materials | 14y ago2012-03-29 | - | View filing |
| DEFA14A | Proxy materials | 15y ago2011-03-29 | - | View filing |
| DEFA14A | Proxy materials | 16y ago2010-03-26 | - | View filing |
| DEFA14A | Proxy materials | 17y ago2009-04-02 | - | View filing |
| DEFA14A | Proxy materials | 21y ago2005-06-01 | - | View filing |
| DEFA14A | Proxy materials | 21y ago2005-05-23 | - | View filing |
| DEFA14A | Proxy materials | 25y ago2001-04-18 | - | View filing |